|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0003195,
umls-concept:C0018787,
umls-concept:C0021467,
umls-concept:C0021469,
umls-concept:C0030685,
umls-concept:C0391871,
umls-concept:C0439799,
umls-concept:C0456387,
umls-concept:C0596235,
umls-concept:C0680255,
umls-concept:C1283071,
umls-concept:C1419779,
umls-concept:C1631597,
umls-concept:C1963578
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
2011-4-20
|
|
pubmed:abstractText |
Catecholaminergic polymorphic ventricular tachycardia (CPVT) is caused by mutations in the cardiac ryanodine receptor (RyR2) or calsequestrin (Casq2) and can be difficult to treat. The class Ic antiarrhythmic drug flecainide blocks RyR2 channels and prevents CPVT in mice and humans. It is not known whether other class I antiarrhythmic drugs also block RyR2 channels and to what extent RyR2 channel inhibition contributes to antiarrhythmic efficacy in CPVT.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Anti-Arrhythmia Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Calcium Channel Blockers,
http://linkedlifedata.com/resource/pubmed/chemical/Calsequestrin,
http://linkedlifedata.com/resource/pubmed/chemical/Flecainide,
http://linkedlifedata.com/resource/pubmed/chemical/Lidocaine,
http://linkedlifedata.com/resource/pubmed/chemical/Procainamide,
http://linkedlifedata.com/resource/pubmed/chemical/Propafenone,
http://linkedlifedata.com/resource/pubmed/chemical/Ryanodine Receptor Calcium Release...,
http://linkedlifedata.com/resource/pubmed/chemical/Sodium Channel Blockers,
http://linkedlifedata.com/resource/pubmed/chemical/casq2 protein, mouse
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Apr
|
|
pubmed:issn |
1941-3084
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
1
|
|
pubmed:volume |
4
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
128-35
|
|
pubmed:meshHeading |
pubmed-meshheading:21270101-Analysis of Variance,
pubmed-meshheading:21270101-Animals,
pubmed-meshheading:21270101-Anti-Arrhythmia Agents,
pubmed-meshheading:21270101-Calcium Channel Blockers,
pubmed-meshheading:21270101-Calsequestrin,
pubmed-meshheading:21270101-Defibrillators, Implantable,
pubmed-meshheading:21270101-Disease Models, Animal,
pubmed-meshheading:21270101-Dose-Response Relationship, Drug,
pubmed-meshheading:21270101-Electric Countershock,
pubmed-meshheading:21270101-Electrocardiography,
pubmed-meshheading:21270101-Flecainide,
pubmed-meshheading:21270101-Humans,
pubmed-meshheading:21270101-Ion Channel Gating,
pubmed-meshheading:21270101-Lidocaine,
pubmed-meshheading:21270101-Male,
pubmed-meshheading:21270101-Mice,
pubmed-meshheading:21270101-Mice, Knockout,
pubmed-meshheading:21270101-Mutation, Missense,
pubmed-meshheading:21270101-Myocytes, Cardiac,
pubmed-meshheading:21270101-Procainamide,
pubmed-meshheading:21270101-Propafenone,
pubmed-meshheading:21270101-Ryanodine Receptor Calcium Release Channel,
pubmed-meshheading:21270101-Sodium Channel Blockers,
pubmed-meshheading:21270101-Tachycardia, Ventricular,
pubmed-meshheading:21270101-Time Factors,
pubmed-meshheading:21270101-Young Adult
|
|
pubmed:year |
2011
|
|
pubmed:articleTitle |
Inhibition of cardiac Ca2+ release channels (RyR2) determines efficacy of class I antiarrhythmic drugs in catecholaminergic polymorphic ventricular tachycardia.
|
|
pubmed:affiliation |
Oates Institute for Experimental Therapeutics, Vanderbilt University School of Medicine, Division of Clinical Pharmacology, Nashville, TN 37232-0575, USA.
|
|
pubmed:publicationType |
Journal Article,
Case Reports,
Research Support, Non-U.S. Gov't,
Research Support, N.I.H., Extramural
|
